Edwards Lifesciences Corporation $EW Shares Sold by Robbins Farley

Robbins Farley decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,954 shares of the medical research company’s stock after selling 391 shares during the quarter. Robbins Farley’s holdings in Edwards Lifesciences were worth $2,186,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Jennison Associates LLC grew its stake in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after purchasing an additional 264,311 shares during the period. Nuveen LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $330,881,000. Invesco Ltd. grew its stake in shares of Edwards Lifesciences by 2.6% during the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after purchasing an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Edwards Lifesciences by 5.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after purchasing an additional 198,882 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of a number of analyst reports. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, July 25th. Piper Sandler increased their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 25th. Dbs Bank upgraded Edwards Lifesciences to a “hold” rating in a research report on Monday, June 2nd. Finally, Mizuho increased their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $86.61.

Edwards Lifesciences Trading Up 1.3%

Shares of EW stock opened at $77.25 on Tuesday. The stock’s fifty day moving average is $78.51 and its two-hundred day moving average is $75.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market capitalization of $45.35 billion, a P/E ratio of 11.11, a PEG ratio of 3.67 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.